# Mirum Pharmaceuticals, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Mirum Pharmaceuticals, Inc.). ## Overview Mirum Pharmaceuticals is a U.S.-based biopharmaceutical company focused on rare diseases, with a commercial portfolio centered on bile acid and cholestatic liver disorder therapies. Its approved medicines include Livmarli, Cholbam and Ctexli, and the company also develops additional rare-disease candidates such as brelovitug and volixibat. ## Products & services • LIVMARLI (maralixibat) for cholestatic pruritus in rare liver diseases • CHOLBAM (cholic acid) capsules for bile acid replacement therapy • CTEXLI (chenodiol) tablets for cerebrotendinous xanthomatosis • Rare-disease commercialization and distribution partnerships • Clinical development of pipeline assets including brelovitug and volixibat - **Commercial rare-disease medicines** (90%) — Approved therapies sold in the U.S. and selected international markets for rare cholestatic and bile acid disorders. - **Bile acid replacement therapies** (8%) — Cholbam and Ctexli products used to treat specific bile acid-related rare diseases. - **Pipeline and clinical development** (2%) — Investigational programs such as brelovitug and volixibat that may expand future revenue. - LIVMARLI (maralixibat) for cholestatic pruritus in ALGS and PFIC - CHOLBAM (cholic acid) capsules for bile acid replacement therapy - CTEXLI (chenodiol) tablets for cerebrotendinous xanthomatosis - Rare-disease commercialization through direct sales and partners - Clinical development of brelovitug for chronic HDV infection - Development of volixibat and other IBAT inhibitor programs ## Customers Mirum sells mainly to specialty pharmacies, authorized distributors and licensed partners that serve patients with rare diseases. End demand comes from physicians treating pediatric and adult patients with cholestatic liver disorders and other ultra-rare conditions, where diagnosis, reimbursement and access support are critical to uptake. - **Specialty pharmacies** (primary) — Dispense Livmarli, Cholbam and Ctexli to patients in the U.S. and Canada and are central to fulfillment. - **Licensed partners and distributors** (primary) — Buy product for resale or distribution in select international markets where Mirum does not fully commercialize directly. - **Physicians and treatment centers** (primary) — Prescribe the medicines for rare liver diseases and drive diagnosis, initiation and ongoing use. - **Payors and government programs** (primary) — Influence access through coverage, reimbursement and gross-to-net deductions, especially in the U.S. - **Patients with rare cholestatic disorders** (primary) — End users of the therapies; demand depends on diagnosis, tolerability and long-term disease management. - Specialty pharmacies dispensing to rare-disease patients in the U.S. and Canada - Authorized distributors and licensed partners in Europe and other markets - Physicians treating ALGS, PFIC and other cholestatic liver diseases - Patients and caregivers needing chronic therapy and access support - Government and commercial payors that determine reimbursement access ## Geography Mirum commercializes directly in the U.S. and Canada and is building its own presence in major European markets, while using partners and distributors in additional countries. Revenue can be lumpy because some markets involve periodic government orders and distributor purchases, which creates quarter-to-quarter variability. - U.S. is the core commercial market for Livmarli, Cholbam and Ctexli - Canada is served through a single specialty pharmacy - Certain European markets are served by Mirum's own commercial team - Additional countries rely on partners, distributors and licensees - Government orders in some markets can create quarterly revenue swings ## Strategy Mirum's strategy is to expand commercial adoption of its approved rare-disease medicines while broadening geographic reach through direct sales and partnerships. At the same time, it is investing in pipeline programs such as brelovitug and seeking label expansion for Livmarli to extend the franchise across additional rare conditions. - **Expand Livmarli commercialization** (short-term) — Livmarli is the main growth engine and the most important franchise for near-term revenue expansion. - **Broaden the addressable market for Livmarli** (medium-term) — New indications can extend the product lifecycle and increase the number of treatable patients. - **Advance pipeline diversification** (medium-term) — Pipeline assets reduce dependence on a small number of commercial products. - Grow Livmarli adoption in ALGS and PFIC across core markets - Expand direct commercial capabilities in Europe and Canada - Use partners and distributors to reach smaller international markets - Pursue new indications through the EXPAND study for Livmarli - Advance brelovitug and other pipeline assets to diversify future revenue - Maintain access and reimbursement to support long-term product uptake ## Risks Mirum depends on a small number of approved medicines, so commercial execution, reimbursement and safety outcomes have an outsized effect on results. The company also faces development risk in its pipeline, foreign-exchange and partner execution risk in international markets, and revenue volatility from periodic distributor and government orders. - **Concentration in a small approved-product portfolio** [high] — Most revenue depends on a few rare-disease medicines, so any demand or safety issue can materially affect sales. - **Reimbursement and access risk** [high] — Rare-disease therapies require payer coverage and patient support, and unfavorable reimbursement can limit uptake. - **Clinical development failure** [high] — Pipeline assets may not prove safe or effective enough for approval, delaying future growth. - **Partner and distributor execution** [medium] — International commercialization relies partly on third parties, reducing control over sales and market access. - **Revenue timing volatility** [medium] — Large periodic orders and government purchasing patterns can shift revenue between quarters. - Heavy reliance on Livmarli and a small approved-product portfolio - Reimbursement and gross-to-net pressure can reduce realized revenue - Clinical development risk for brelovitug, volixibat and label expansion - Partner/distributor dependence can limit control over international sales - Quarterly revenue volatility from periodic orders and launch timing - Competition from larger pharma and other IBAT developers ## Accounting Mirum's revenue recognition is sensitive to timing because product sales are recorded when control transfers, while distributor and partner arrangements require estimates of consideration and sell-through. The company also faces quarter-to-quarter volatility from periodic orders, and its convertible notes create non-cash interest expense and dilution-related accounting complexity. - **Revenue recognition for distributor and partner sales** — Quarterly product sales can be volatile, especially during launches - **Gross-to-net deductions and patient assistance** — Net sales can differ materially from gross prescription demand - **Convertible notes accounting** — Raises reported interest expense versus cash interest paid - **Foreign currency translation and transaction effects** — Can add volatility to non-operating results - Product revenue is recognized when control transfers, not when cash is received - Distributor and partner sales require estimates that can change quarterly - Periodic government and partner orders can distort quarterly comparability - Convertible notes create interest expense from amortization and discount accretion - Foreign-currency gains and losses affect other income, net --- *Last updated: 2026-04-28T20:27:22.119125+00:00*